Edition:
United States

Agios Pharmaceuticals Inc (AGIO.OQ)

AGIO.OQ on NASDAQ Stock Exchange Global Select Market

68.80USD
16 Jan 2018
Change (% chg)

-- (--)
Prev Close
$68.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
149,357
52-wk High
$76.02
52-wk Low
$39.25

Select another date:

Mon, Jan 8 2018

BRIEF-Agios Outlines Key 2018 Priorities Expanding Clinical And Research Programs To Drive Long Term Value

* AGIOS OUTLINES KEY 2018 PRIORITIES EXPANDING CLINICAL AND RESEARCH PROGRAMS TO DRIVE LONG TERM VALUE

BRIEF-Agios Submits New Drug Application To The FDA For Ivosidenib

* AGIOS SUBMITS NEW DRUG APPLICATION TO THE FDA FOR IVOSIDENIB FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY AML AND AN IDH1 MUTATION

BRIEF-Agios Pharmaceuticals Presents New Safety Data From Study on Leukemia Drug

* PRESENTS NEW SAFETY DATA FROM PHASE 1 EXPANSION STUDY EVALUATING ORAL IVOSIDENIB IN PATIENTS WITH R/R AML AND IDH1 MUTATION

Promising responses seen with Agios leukemia drug in study

Nearly a third of patients with an advanced form of a fast-progressing leukemia who carry a specific genetic mutation experienced a complete or near complete response to an experimental Agios Pharmaceuticals drug, according to data from an early stage trial released on Monday.

Promising responses seen with Agios leukemia drug in study

Dec 11 Nearly a third of patients with an advanced form of a fast-progressing leukemia who carry a specific genetic mutation experienced a complete or near complete response to an experimental Agios Pharmaceuticals drug, according to data from an early stage trial released on Monday.

BRIEF-Agios Pharmaceuticals Files For Potential Mixed Shelf Offering

* AGIOS PHARMACEUTICALS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text: (http://bit.ly/2yOMDeC) Further company coverage:

BRIEF-Agios presents updated phase 1 data from dose expansion cohort of ivosidenib

* Agios presents updated phase 1 data from dose expansion cohort of ivosidenib (AG-120) in patients with IDH1 mutant positive glioma

BRIEF-Agios reports Q3 revenue $11.4 million

* Agios Pharmaceuticals Inc - Qtrly ‍net loss per share $1.59 Source text for Eikon: Further company coverage:

BRIEF-Agios posts Q2 loss per share $1.78‍​

* Agios Pharmaceuticals Inc - ‍collaboration revenue was $11.3 million for quarter ended June 30, 2017, compared to $7.0 million for comparable period in 2016​

BRIEF-Agios Pharma says FDA approves Idhifa for treating relapsed/refractory Acute Myeloid Leukemia

* FDA grants approval of Idhifa, the first oral targeted therapy for adult patients with relapsed/refractory acute myeloid leukemia and an IDH2 mutation Source text for Eikon: Further company coverage:

Select another date: